Exploring Recent Advances in Dopaminergic Drug Therapy for Parkinson's Disease: Efficacy and Safety Profiles
Main Article Content
Keywords
Parkinson's disease, dopaminergic therapy, efficacy, safety, motor function, adverse effects, quality of life.
Abstract
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by depletion of dopaminergic neurons, leading to motor and non-motor signs. Recent advancements in dopaminergic drug therapy have shown promise in managing these symptoms, yet the efficacy and safety profiles of these therapies require comprehensive evaluation.
Aim: This research aimed to explore effectiveness and protection profiles of recent advances in dopaminergic drug therapy for Parkinson's disease.
Methods: An overall of 300 patients detected having Parkinson's disease were included in this resaerch, conducted at Liaquat University of Medical and Health Sciences, Jamshoro, and Isra University, Hyderabad. The study spanned from May 2023 to October 2023. Patients were administered various dopaminergic therapies, and their responses were monitored through clinical evaluations, motor function assessments, and adverse event reporting. Data were analyzed to determine the efficacy and safety of these therapies.
Results: The study observed significant improvements in motor function among patients receiving advanced dopaminergic therapies. The Unified Parkinson's Disease Rating Scale (UPDRS) scores demonstrated the marked decrease in motor signs. Furthermore, patient-reported results indicated enhanced quality of life. However, adverse effects such as dyskinesia and hallucinations were noted in a subset of patients, necessitating careful management and monitoring.
Conclusion: Recent advances in dopaminergic drug therapy for Parkinson's disease were found to be effective in improving motor function and overall quality of life. Despite the noted adverse effects, these therapies presented a favorable benefit-risk ratio, underscoring their potential in PD management. Ongoing monitoring and individualized treatment approaches are recommended to optimize therapeutic outcomes
References
2. Fabbri M, Barbosa R, Rascol O. Off-time treatment options for Parkinson’s disease. Neurology and therapy. 2023 Apr;12(2):391-424.
3. Isaacson SH, Hauser RA, Pahwa R, Gray D, Duvvuri S. Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment. Clinical Parkinsonism & Related Disorders. 2023 Jul 7:100212.
4. Cha Y, Park TY, Leblanc P, Kim KS. Current status and future perspectives on stem cell-based therapies for parkinson’s disease. Journal of Movement Disorders. 2023 Jan;16(1):22.
5. Wamelen DJ, Leta V, Chaudhuri K, Jenner P. Future Directions for Developing Non-dopaminergic Strategies for the Treatment of Parkinson’s Disease. Current Neuropharmacology. 2024 Aug 1;22(10):1606-20.
6. Degirmenci Y, Angelopoulou E, Georgakopoulou VE, Bougea A. Cognitive impairment in Parkinson’s disease: an updated overview focusing on emerging pharmaceutical treatment approaches. Medicina. 2023 Oct 1;59(10):1756.
7. Masood N, Jimenez-Shahed J. Effective management of “OFF” episodes in Parkinson’s disease: emerging treatment strategies and unmet clinical needs. Neuropsychiatric Disease and Treatment. 2023 Dec 31:247-66.
8. Sako W, Kogo Y, Koebis M, Kita Y, Yamakage H, Ishida T, Hattori N. Comparative efficacy and safety of adjunctive drugs to levodopa for fluctuating Parkinson’s disease-network meta-analysis. npj Parkinson's Disease. 2023 Oct 19;9(1):143.
9. Yunusa I. Pimavanserin’s Safety Profile: Insights from a Phase 3b Clinical Trial. Journal of Alzheimer's Disease. 2024 May 18(Preprint):1-4.
10. McGarry A, Rosanbalm S, Leinonen M, Olanow CW, To D, Bell A, Lee D, Chang J, Dubow J, Dhall R, Burdick D. Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial. The Lancet Neurology. 2024 Jan 1;23(1):37-45.
11. Cavallieri F, Cury RG, Guimarães T, Fioravanti V, Grisanti S, Rossi J, Monfrini E, Zedde M, Di Fonzo A, Valzania F, Moro E. Recent Advances in the Treatment of Genetic Forms of Parkinson’s Disease: Hype or Hope?. Cells. 2023 Feb 27;12(5):764.
12. Chen XT, Zhang Q, Chen FF, Wen SY, Zhou CQ. Comparative efficacy and safety of six non-ergot dopamine-receptor agonists in early Parkinson's disease: a systematic review and network meta-analysis. Frontiers in Neurology. 2023 Jun 16;14:1183823.
13. Li W, Zhang H, Zhang Y, Wang K, Hui J, Yi Z. Comparison of the effectiveness, safety, and costs of anti‐Parkinson drugs: a multiple‐center retrospective study. CNS Neuroscience & Therapeutics. 2024 Apr;30(4):e14531.
14. Saini N, Singh N, Kaur N, Garg S, Kaur M, Kumar A, Verma M, Singh K, Sohal HS. Motor and non-motor symptoms, drugs, and their mode of action in Parkinson’s disease (PD): a review. Medicinal Chemistry Research. 2024 Apr;33(4):580-99.
15. Khan MA, Haider N, Singh T, Bandopadhyay R, Ghoneim MM, Alshehri S, Taha M, Ahmad J, Mishra A. Promising biomarkers and therapeutic targets for the management of Parkinson's disease: recent advancements and contemporary research. Metabolic Brain Disease. 2023 Mar;38(3):873-919.
16. Neha, Mazahir I, Khan SA, Kaushik P, Parvez S. The Interplay of Mitochondrial Bioenergetics and Dopamine Agonists as an Effective Disease-Modifying Therapy for Parkinson’s Disease. Molecular Neurobiology. 2024 Mar 11:1-8.
17. Woitalla D, Buhmann C, Hilker-Roggendorf R, Höglinger G, Koschel J, Müller T, Weise D. Role of dopamine agonists in Parkinson's disease therapy. Journal of Neural Transmission. 2023 Jun;130(6):863-73.
18. Kim MS, Yoon S, Choi J, Kim YJ, Lee G. Stem Cell-Based Approaches in Parkinson’s Disease Research. International Journal of Stem Cells. 2024 Mar 7.
19. Ayuso P, Jiménez-Jiménez FJ, Gómez-Tabales J, Alonso-Navarro H, García-Martín E, Agúndez JA. An update on the pharmacogenetic considerations when prescribing dopamine receptor agonists for Parkinson’s disease. Expert Opinion on Drug Metabolism & Toxicology. 2023 Jul 3;19(7):447-60.
20. Wolff A, Schumacher NU, Pürner D, Machetanz G, Demleitner AF, Feneberg E, Hagemeier M, Lingor P. Parkinson’s disease therapy: what lies ahead?. Journal of Neural Transmission. 2023 Jun;130(6):793-820.
21. Aldred J, Freire-Alvarez E, Amelin AV, Antonini A, Bergmans B, Bergquist F, Bouchard M, Budur K, Carroll C, Chaudhuri KR, Criswell SR. Continuous subcutaneous foslevodopa/foscarbidopa in Parkinson’s disease: Safety and efficacy results from a 12-month, single-arm, open-label, phase 3 study. Neurology and Therapy. 2023 Dec;12(6):1937-58.
22. Aldred J, Freire-Alvarez E, Amelin AV, Antonini A, Bergmans B, Bergquist F, Bouchard M, Budur K, Carroll C, Chaudhuri KR, Criswell SR. Continuous subcutaneous foslevodopa/foscarbidopa in Parkinson’s disease: Safety and efficacy results from a 12-month, single-arm, open-label, phase 3 study. Neurology and Therapy. 2023 Dec;12(6):1937-58.
23. Bougea A. Some Novel Therapies in Parkinson’s Disease: A Promising Path Forward or Not Yet? A Systematic Review of the Literature. Biomedicines. 2024 Feb 29;12(3):549.
24. Cheng B, Huang S, Huang Q, Zhou Z, Bao Y. The efficacy and safety of medication for treating overactive bladder in patients with Parkinson's disease: a meta-analysis and systematic review of randomized double-blind placebo-controlled trials. International Urogynecology Journal. 2023 Sep;34(9):2207-16.
25. Phillips O, Ghosh D, Fernandez HH. Parkinson Disease Dementia Management: An Update of Current Evidence and Future Directions. Current Treatment Options in Neurology. 2023 May;25(5):93-119.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.